KAPA - Margin resik Kairos Pharma

Tandha merek Kairos Pharma Inc (KAPA)

Strong physician confidence in Kairos Pharma Ltd (KAPA) innovations sustains investor interest, as evidenced by the revenue margin indicator. The 0.00 mark indicates the current yield level. Business stability relies on the development of unique molecules in US centers, while the diversification of the clinical trial portfolio for prostate and lung cancer treatment minimizes potential failure risks.

Margin dodolan perusahaan Kairos Pharma Limited (KAPA): kanggo periode 17.09.2024 - 20.11.2026

Rincian analitis perusahaan kairospharma.com (KAPA)

- nilai pasar lan prakiraan target analis:
Ringkesan analitik perusahaan:Kairos Pharma Inc - KAPA
Produk asil prodhuksi Kairos Pharma Ltd

The performance of Kairos Pharma Ltd (KAPA) is clearly reflected through the net sales margin spread. This indicator determines the portion of profit remaining from revenue after deducting all operating and tax expenses. The calculation allows for a precise measurement of the monetization efficiency of each product unit. For biotech companies, volatility in this metric often signals disruptions in raw material supply chains. Stable growth in the spread confirms the capital's resilience to geopolitical risks.

Analisis pesaing

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|ANL - Margin resik|Margin resik verupharma.com|TPST: Margin dodolan resik|XLO - Margin dodolan perusahaan|Margin resik Renovaro|Margin dodolan resik muraloncology.com|Margin dodolan resik OKUR|CytoMed Therapeutics Limited (GDTC) - Tingkat bathi miturut bathi resik|Margin dodolan resik CRIS (Curis, Inc.)|APLM: Rentabilitas dodolan resik|Tharimmune Corporation - Margin dodolan resik|ADVB: Margin resik|GNPX: Margin dodolan resik|CLDI (Calidi Biotherapeutics Inc.) - Margin resik|Margin resik Sunshine Biopharma, Inc.|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)